Overview

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Status:
Active, not recruiting

Trial end date:
2022-04-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Olaratumab
Pembrolizumab